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Abstract
Emergence agitation (EA) can be a distressing side effect of pediatric anesthesia. We observed no 
recurrence of EA after a low-dose ketamine infusion was added to propofol total intravenous 
anesthesia in a series of seven pediatric oncology patients repetitively anesthetized for radiation 
therapy. EA had been documented in all seven patients but did not recur in any of 122 subsequent 
anesthetics in which this technique was used. Based on these findings, we recommend the addition 
of low-dose ketamine to propofol infusions for total intravenous anesthesia in order to prevent EA 
in children with a history of EA.
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Introduction
Propofol total intravenous anesthesia (TIVA) is an effective and well-tolerated anesthetic 
technique that allows smooth induction and rapid recovery, making it ideal for procedural 
sedation of children [1-4]. However, approximately 3.7% of children experience emergence 
agitation (EA) after propofol TIVA [5, 6]. This frequency is considerably less than that 
reported with sevoflurane (23.1%) [6], but effective prevention of EA has remained elusive. 
The efficacy of fentanyl [7, 8], clonidine [9], oxycodone [10], dexmedetomidine [11], 
midazolam [12], and ketamine [13, 14] for the prevention of EA after inhalation anesthesia 
has been investigated, but we are unaware of any studies of adjunct anesthetic agents for 
prevention of EA after propofol anesthesia. We describe a series of seven pediatric oncology 
patients repetitively anesthetized for radiation therapy with propofol TIVA who experienced 
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documented EA. EA did not recur in any of the 122 subsequent anesthetics in these patients, 
in which a low-dose ketamine infusion was added to propofol TIVA.
Materials and Methods
Anesthetic Technique
Propofol TIVA is the standard regimen for radiation therapy in young children at our 
institution. For patients with a history of agitation on emergence from propofol or with a 
source of pain (e.g., recent postoperative status), the propofol-based regimen may be 
supplemented with benzodiazepines, opioids, and/or ketamine. For patients with allergy to 
propofol or a history of intolerance, a sedation regimen comprising combinations of opioid, 
benzodiazepine and/or ketamine is used. Propofol anesthesia is induced by administering 
successive boluses of 1 mg/kg until loss of consciousness occurs. Additional boluses are 
administered if the child responds to stimulation during positioning for radiation. A propofol 
infusion is then delivered at variable rates of 100 to 250 mcg/kg/min, via a Baxter AS50 
auto-syringe infusion pump (Deerfield, Illinois).
When the ketamine-propofol technique was utilized, the two drugs were mixed together in a 
single syringe. The combination was administered as successive boluses until loss of 
consciousness was achieved, and was then infused throughout the procedure. Each bolus 
delivered a dose of 1 mg∙kg-1 of propofol. The continuous infusion delivered 150-250 
mcg∙kg-1min-1of propofol.
Data Collection
Institutional Review Board approval was obtained to retrospectively review the records of 
seven patients whose propofol TIVA for radiation therapy had been supplemented with a 
low-dose ketamine infusion over a period of 2 years at St. Jude Children's Research Hospital 
(St. Jude), a tertiary-care pediatric cancer research center.
We reviewed the recovery room nursing notes for all anesthetics in the 7 patients to identify 
the anesthetic session after which EA was first diagnosed and documented as inconsolable 
crying, thrashing behavior, or severe agitation. We then identified the anesthetic session 
when ketamine was first given and the number of sessions in which the ketamine-propofol 
regimen was used for each patient.
Results
A low-dose ketamine was added to the anesthetic regimens of patients known to have 
experienced EA in an attempt to prevent recurrence. In these 7 patients in whom EA had 
been documented in conjunction with previous anesthetics, ketamine and propofol were the 
only agents used in all subsequent anesthetics, for a total of 122 anesthetic sessions. Patient 
age, oncology diagnosis, and weight are summarized in Table 1.
The number of sessions in which the ketamine-propofol regimen was used for each patient is 
presented in Table 2. Table 3 summarizes the procedure duration, the dose and infusion rate 
of ketamine and propofol, and the dose ratio of ketamine to propofol for each patient.
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The seven patients underwent a mean of 15.4 anesthetics (median, 12.5; range, 4-28) that 
included a low-dose ketamine infusion. The most frequent dose ratio of ketamine to 
propofol was 1:10 (range, 1:7 to 1:20). No EA was documented during recovery from 
ketamine-propofol anesthetics.
Discussion
EA after inhalation anesthesia has been well described [12, 15-17]. EA after propofol 
anesthesia has been less completely described [5, 6], and there are no reports on the 
prevention of EA following propofol TIVA in children. Our case series is the first to report 
the successful use of a low-dose ketamine infusion in preventing EA after propofol TIVA.
The patients in this series formed a fairly homogeneous group. All were aged between 2.5 
and 4.5 years and three had a diagnosis of brain tumor. The central nervous system 
pathology in these patients and the pattern of repetitive daily anesthetics may have increased 
the likelihood of EA. However, it remains unclear whether either or both of these factors 
contribute significantly to the onset of EA.
Aside from their possible role in the etiology of EA, repetitive anesthetics for radiation 
therapy exacerbate the burden of EA. In this context, EA is highly disturbing to parents, 
patients, and recovery room personnel. Children are also at risk of physical harm during 
these episodes, and the need for additional supervision and medication often prolongs the 
recovery process [18, 19]. Therefore, it is important in our setting to minimize the incidence 
of EA.
Because the underlying cause of EA is unknown and a multitude of contributory factors, 
including preoperative anxiety, pain, and metabolic imbalances, have been implicated [9, 
20], no single preventive therapy has been established. A number of agents, including 
fentanyl [7, 8], clonidine [9], oxycodone [10], dexmedetomidine [11], and midazolam [12], 
have been tried with variable success in preventing or treating EA.
Ketamine has recently been used to prevent EA associated with inhalation anesthetic agents 
[13, 14]. Kararmaz et al. found that 6 mg∙kg-1 oral ketamine given to children 30 minutes 
before adenotonsillectomy under desflurane anesthesia reduced the incidence of EA from 
56% to 18% [13]. Dalens et al. showed a reduced incidence of EA in children given 0.25 
mg∙kg-1 of intravenous ketamine at the end of MRI procedures under sevoflurane anesthesia 
(12% vs. 36% in the control group) [14]. Our case series adds to these findings that 
intravenous low-dose ketamine may be useful in preventing EA in children undergoing 
TIVA with propofol.
After we began using the ketamine-propofol technique, children who had previously 
experienced documented EA had no further episodes. In most patients (5 of 7), ketamine 
was added during the next anesthetic session after EA was documented. In two patients 
(cases 3 and 7), opioids were used in the next anesthetic session but were ineffective, and 
low-dose ketamine was started during the following session. In 5 of our 7 patients, EA was 
identified relatively early (by the fifth anesthetic session).
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Our case series is not the first to report the use of ketamine in combination with propofol in 
children, but it is the first to examine the use of this combination to prevent EA after 
propofol TIVA. Several recent studies have examined low-dose ketamine with propofol for 
procedural sedation in children, mainly assessing the regimen's effect on hemodynamic 
stability [21-24]. These studies found that low-dose ketamine effectively offsets the 
cardiorespiratory depression caused by propofol while providing adequate sedation and 
analgesia. Willman et al. [25] demonstrated the safety and efficacy of administering the 
ketamine-propofol (“ketofol”) combination from a single syringe to children and adults 
undergoing procedures in the emergency department.
Prospective randomized, controlled trials are needed to confirm the efficacy of ketamine in 
preventing EA and to compare it to other adjuvant agents. Further, we have used of this 
technique only in patients aged 5 years or less, and its effectiveness may differ in other age 
groups.
Low-dose ketamine infused in combination with propofol throughout the procedure appears 
to prevent EA in young children who undergo repetitive anesthesia for radiation therapy.
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Table 1
Patient age, oncology diagnosis, and weight
Case Oncology diagnosis Agea (y) Weighta (kg)
1 Primitive neuro-ectodermal tumor 3.5 13.6
2 Rhabdomyosarcoma 3 15
3 Ependymoma 3 22
4 Neuroblastoma 3 12.5
5 Ependymoma 5 18.6
6ab Neuroblastoma 3 15
6bb Neuroblastoma 2.5 12.5
7 Wilms tumor 4.5 17
a
Measured at time of first anesthetic for radiation therapy
b
Patient 6 received two separate radiation therapy courses 8 months apart.
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Table 2
Anesthetic sessions with ketamine
Case Session EA diagnosed Session ketamine introduced Sessions with Ketamine-Propofol/ Total Sessions
1 3 4 28/31
2 3 4 26/29
3 5 7 26/32
4 0a 1 15/16
5 25 26 10/35
6ab 8 9 8/17
6bb 11 12 6/17
7 1 3 4/9
EA, emergence agitation
a
Patient 4 was diagnosed with EA prior to their first radiation treatment.
b
Patient 6 received two separate radiation therapy courses 8 months apart.
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